MSLN and mesothelioma: Leveraging the cross-reactivity of JZQ-B4 variants to mouse MSLN (Figure 2B), we assessed the efficacy and toxicity of CAR affinity variants utilizing a subcutaneous mesothelioma tumor model with MSTO-211H/hMSLN cells (Figure 4A).